Kodiak Sciences Quarterly Income Statement
NASDAQ: KODHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
99.87+5.61 (+5.95%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kodiak Sciences revenue and earnings
Kodiak Sciences reported a net loss of $65.6 million, compared with a loss of $54.3 million a year earlier. Diluted earnings per share came in at -$1.05.
Summary generated from market data by MetaCap's automated system. Methodology
Kodiak Sciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 66.84M | 59.78M | 57.45M | 62.35M | 55.51M | 59.07M | 46.18M | 46.63M | 47.98M | 46.05M | 63.37M | 54.50M |
| Research & Development | 56.08M | 48.55M | 45.49M | 50.48M | 42.76M | 43.64M | 31.77M | 31.88M | 32.51M | 29.93M | 46.63M | 36.19M |
| Operating Income | -66.84M | -59.78M | -57.45M | -62.35M | -55.51M | -59.07M | -46.18M | -46.63M | -47.98M | -46.05M | -63.37M | -54.50M |
| Interest Expense | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 5.00K |
| Other Income (Expense) | -60.00K | -22.00K | -40.00K | -22.00K | -44.00K | 10.00K | -56.00K | -25.00K | -88.00K | -337.00K | -39.00K | -38.00K |
| Net Income | -65.64M | -58.16M | -56.74M | -61.46M | -54.31M | -57.46M | -44.10M | -43.95M | -45.12M | -43.04M | -59.52M | -50.01M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.05 | -0.94 | -1.04 | -1.16 | -1.03 | -1.09 | -0.83 | -0.84 | -0.86 | -0.82 | -1.14 | -0.95 |
| EPS (Diluted) | -1.05 | -0.94 | -1.04 | -1.16 | -1.03 | -1.09 | -0.83 | -0.84 | -0.86 | -0.82 | -1.14 | -0.95 |
| Shares Outstanding (Basic) | 62.63M | 61.86M | — | 52.86M | 52.78M | 52.75M | — | 52.62M | 52.55M | 52.51M | — | 52.46M |
| Shares Outstanding (Diluted) | 62.63M | 61.86M | — | 52.86M | 52.78M | 52.75M | — | 52.62M | 52.55M | 52.51M | — | 52.46M |
| EBITDA | -62.73M | -55.67M | -52.91M | -57.77M | -50.92M | -54.47M | -41.55M | -41.95M | -43.29M | -41.35M | -58.65M | -49.50M |
This table shows 12 quarterly periods of Kodiak Sciences's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow KOD's reporting calendar. What is a income statement?